NCT02318082View on ClinicalTrials.gov

Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

October 31, 2017

Study Completion Date

April 22, 2020

Conditions
Chronic Versus Graft Host Disease
Interventions
DRUG

Interleukin-2

Trial Locations (1)

02215

Dana-Farber Cancer Insitute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT02318082 - Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD | Biotech Hunter | Biotech Hunter